Policy & Regulation
Calico Life Sciences' ABBV-CLS-628S granted US FDA Orphan Drug Designation
6 November 2025 - Calico Life Sciences LLC, a biotechnology company focused on ageing and age-related diseases, founded by Alphabet Inc (NASDAQ:GOOG) and Arthur D. Levinson, announced on Wednesday tha...
Lunai Bioworks publishes breakthrough on second-generation allogeneic dendritic cell therapy in vaccines
5 November 2025 - Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefence company, on Wednesday announced the publication of a landmark study detailing its second-generation allogen...
Oxford Nanopore and bioMérieux introduce AmPORE-TB for rapid tuberculosis resistance characterisation
5 November 2025 - French diagnostics company bioMérieux (Euronext Paris:BIM) and UK-based molecular sensing technology company Oxford Nanopore Technologies (LON:ONT) on Wednesday announced the ...
Cizzle Biotechnology signs Letter of Intent with UK diagnostic provider
5 November 2025 - UK based diagnostics developer of early cancer tests Cizzle Biotechnology Holdings plc (LSE: CIZ) announced on Wednesday that it has signed a Letter of Intent with a leading UK medic...
HUTCHMED completes enrollment of global Phase III SAFFRON trial for ORPATHYS and TAGRISSO combination in lung cancer
5 November 2025 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq/AIM: HCM) (HKEX: 13) announced on Wednesday that it has completed patient enrollment for its global Phase III SAFFRON trial...
Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS
5 November 2025 - Clinical-stage biopharmaceutical company Spinogenix Inc on Tuesday reported positive topline results from its completed Phase 2a study for SPG302 in patients with Amyotrophic Lateral...